Figure 5 | British Journal of Cancer

Figure 5

From: Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR

Figure 5

Antitumour effect of ch806 on U87MG.de2-7 glioma xenograft growth rates. U87MG.de2-7 cells (3 × 106) were injected s.c. into both flanks of 4–6-week-old BALB/c nude mice at day 0. Antibody treatment commenced on day 7 post-tumour-cell inoculation and consisted of six i.p. injections over 2 weeks of 1 mg ch806 (▴), 1 mg mAb 806 (•), 1 mg 528 anti-EGFR (▾), or vehicle control (▪) on days 7, 9, 11, 14, 16 and 18 (arrows). Mean tumour volume (bars;±s.e.) for each treatment group (n=5) is presented. *P=0.04, mAb 806 vs control, day 30. **P=0.001, ch806 vs control, day 30. ***P=0.014, ch806 vs mAb 806, day 30; P=0.025, ch806 vs 528, day 30.

Back to article page